Globus Medical Inc. Class A Common Stock vs Micron Technology, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Micron Technology, Inc. trades at $879.63 (market cap $1.03T). The key difference: Micron Technology, Inc. is far larger — about 100.5× Globus Medical Inc. Class A Common Stock's market cap, and Micron Technology, Inc. pays a 0.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Micron Technology, Inc. for 49 Days on average.
| GMED | MU | |
|---|---|---|
Market Cap | $10.25B | $1.03T |
Volume | 1,059,528 | 27,296,988 |
Sector | Health | Technology |
52-Week High | $96.82 | $1.21K |
52-Week Low | $58.33 | $191.94 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $9.76B | $996.01B |
Dividend Yield | — | 0.07% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Micron Technology (MU) trades at $953.19, down 3.62% on the day, amid strong fundamentals including a P/E of 12.82 and net income margin of 63.8%. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $33.42 exceeding expectations. Technical indicators show a bullish moving average signal but neutral oscillators, with support at $954. Revenue surged to $37.38 billion in 2025, and cash flow from operations reached $17.53 billion, reflecting robust operational performance.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Risks include cyclical memory pricing and potential growth deceleration. Analyst consensus is strongly bullish with an average price target of $1,590, suggesting significant upside. Institutional sentiment supports growth, but investors should monitor competitive pressures and macroeconomic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →